---
layout: work
title: Main Scientific Publication
---

### **Methodology**
* Towards filling the gap around recurrent events in high dimensional framework: literature review and early comparison [[preprint](https://arxiv.org/abs/2203.15694)] (2023). **Murris J**, Charles-Nelson A, Lavenu A, Katsahian S. *Accepted for publication*

* Health technology assessment of artificial intelligence-based medical devices: what healthcare stakeholders need to know on algorithm performance, interpretability and explainability [[paper](https://www.mcpdigitalhealth.org/article/S2949-7612(23)00010-X/fulltext)] (2023). **Murris J**\*, Farah L\*, Borget I, Martelli N, Katsahian S. *Mayo Clinic Proceedings: Digital Health*

* A comparison of methods for high-dimensional survival data on small samples: hyperparameter optimization and validation [[short paper](https://jds22.sciencesconf.org/data/pages/LivretJdS22_version_longue.pdf)] (2022). Lavenu A, **Murris J**, Mareau A, Rouzé T, Fromont M, Gares V, Katsahian S. *53ème Journées de Statistique de la SFdS*

### **Clinical studies**
* Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and impose poor clinical outcome of patients with lung cancer [[paper](https://www.nature.com/articles/s42003-022-04356-y)] (2022). Devi-Marulkar P, […] **Murris J**, et al. *Communications Biology*

* Protocol for Fever Control Using External Cooling in Mechanically Ventilated Patients with Septic Shock: SEPSISCOOL II Randomised Controlled Trial (2023). Arnoux A, **Murris J**, et al. *Under review*

* Risk factors for thromboembolic events in patients hospitalized for Covid-19 pneumonia in general ward and requiring oxygen supply (2023). Degrave R, **Murris J**, et al. *Under review*

* A systematic review and meta-analysis of post-thrombotic syndrome, recurrent thromboembolism, and bleeding after upper extremity vein thrombosis (2022). Espitia O, Raimbeau A, Planquette B, Katsahian S, Sanchez O, Bénichou A, **Murris J**. *Under review*

* Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) [[paper](https://pubmed.ncbi.nlm.nih.gov/34091420/)] (2021). Gogas H, […] **Murris J**, et al. *European Journal of Cancer*
